Cargando…

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*

Background: An elevated level of low-density lipoprotein cholesterol (LDL-C) constitutes one of the most important modifiable risk factors for cardiovascular disease (CVD). Individuals with heterozygous familial hypercholesterolaemia (HeFH) are particularly vulnerable to CVD events. The addition of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borissov, Borislav, Urbich, Michael, Georgieva, Boryana, Tsenov, Svetoslav, Villa, Guillermo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757229/ https://www.ncbi.nlm.nih.gov/pubmed/29321830 http://dx.doi.org/10.1080/20016689.2017.1412753

Ejemplares similares

Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
por: Grégoire, Jean, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
por: Alghamdi, Ahmed, et al.
Publicado: (2021)

Coronary artery calcium among patients with heterozygous familial hypercholesterolaemia
por: Tada, Hayato, et al.
Publicado: (2023)

Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK
por: Kerr, Marion, et al.
Publicado: (2017)

Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia
por: Pears, Robert, et al.
Publicado: (2015)

Cost-Effectiveness of Screening Algorithms for Familial Hypercholesterolaemia in Primary Care
por: Jones, Matthew, et al.
Publicado: (2022)

Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis
por: Akioyamen, Leo E, et al.
Publicado: (2017)

Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
por: Gandra, Shravanthi R., et al.
Publicado: (2016)

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
por: Moriarty, Patrick M., et al.
Publicado: (2016)

Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis
por: Kinnear, Fiona J, et al.
Publicado: (2019)

Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review
por: Mohd Nor, Noor Shafina, et al.
Publicado: (2019)

Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic review
por: Mansilla-Rodríguez, María Elena, et al.
Publicado: (2023)

Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial
por: Raal, Frederick, et al.
Publicado: (2023)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries
por: Ramaswami, Uma, et al.
Publicado: (2020)

The genetics and screening of familial hypercholesterolaemia
por: Henderson, Raymond, et al.
Publicado: (2016)

Genetic Architecture of Familial Hypercholesterolaemia
por: Sharifi, Mahtab, et al.
Publicado: (2017)

Tendon xanthomas in familial hypercholesterolaemia
por: Bharath, Gopinath, et al.
Publicado: (2020)

The reduced cost of providing a nationally recognised service for familial hypercholesterolaemia
por: Pears, Robert, et al.
Publicado: (2014)

Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
por: Landmesser, Ulf, et al.
Publicado: (2020)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
por: Kastelein, John J.P., et al.
Publicado: (2015)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

Cardiovascular risk stratification in familial hypercholesterolaemia
por: Sharifi, Mahtab, et al.
Publicado: (2016)

Serum paraoxonase activity in familial hypercholesterolaemia
por: Kotani, Kazuhiko, et al.
Publicado: (2023)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
por: Neil, Andrew, et al.
Publicado: (2008)

Economic Burden of Cervical Cancer in Bulgaria
por: Lebanova, Hristina, et al.
Publicado: (2023)

Ecological status assessment of Skalenski Lakes (Bulgaria)
por: Teneva, Ivanka, et al.
Publicado: (2014)

A Snapshot Picture of the Fungal Composition of Bee Bread in Four Locations in Bulgaria, Differing in Anthropogenic Influence
por: Dimov, Svetoslav G., et al.
Publicado: (2021)

Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?
por: Hang, Shyann, et al.
Publicado: (2021)

Familial hypercholesterolaemia: cholesterol efflux and coronary disease
por: Versmissen, Jorie, et al.
Publicado: (2016)

Management of homozygous familial hypercholesterolaemia in two brothers
por: Real, José, et al.
Publicado: (2018)

Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis
por: Poznyak, Anastasia V., et al.
Publicado: (2022)

Dietary intervention for children and adolescents with familial hypercholesterolaemia
por: Capra, Maria Elena, et al.
Publicado: (2023)

Regional health and social inequalities in Bulgaria
por: Tsanova, D, et al.
Publicado: (2023)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia
por: Anagnostopoulou, Katherine K, et al.
Publicado: (2009)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
por: Wan, Yuansheng, et al.
Publicado: (2023)

How do the experiences and beliefs of adults and children with heterozygous familial hypercholesterolaemia influence their adherence to treatment? A systematic review of qualitative evidence protocol
por: Kinnear, Fiona J., et al.
Publicado: (2018)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
por: Huang, Chin-Chou, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qo5ogmj3uqli6cufcrquv050dv